Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Broadcom stock analysis & discuss the risks and upside potential of AVGO stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor20 Dec 2025, 00:21 UTC
Video preview for Friends! In this video, I'm going to do a Broadcom stock analysis & discuss the risks and upside potential of AVGO stock
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
0
Canonical correct result
Failed
1
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

Broadcom (AVGO) has shown strong revenue growth through acquisitions, with a current price of $329.88. Analysts expect AI chip sales to double, contributing significantly to revenue. The stock's forward P/E ratio is 69, with a 5-year target price of $613.55, suggesting an 89% upside. Oracle (ORCL) faces a more challenging financial situation with high debt and negative free cash flow. The stock is trading at $180.03, down 18% in the past month. Its forward P/E is around 22, significantly lower than AVGO, indicating potential overvaluation concerns, with a price target around $280 for a double in 5 years. However, the current valuation might be fair rather than undervalued.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.